Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crescent Biopharma (CBIO) Non-cash Items (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed Non-cash Items for 8 consecutive years, with $6.0 million as the latest value for Q1 2025.

  • On a quarterly basis, Non-cash Items rose 113.8% to $6.0 million in Q1 2025 year-over-year; TTM through Mar 2025 was $6.0 million, a 113.8% increase, with the full-year FY2023 number at $887696.0, down 80.05% from a year prior.
  • Non-cash Items was $6.0 million for Q1 2025 at Crescent Biopharma, up from $1.2 million in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $6.7 million in Q3 2021 to a low of $1500.0 in Q1 2021.
  • A 5-year average of $3.2 million and a median of $3.9 million in 2022 define the central range for Non-cash Items.
  • Peak YoY movement for Non-cash Items: crashed 99.95% in 2021, then skyrocketed 38214.72% in 2022.
  • Crescent Biopharma's Non-cash Items stood at $4.9 million in 2021, then fell by 9.86% to $4.4 million in 2022, then tumbled by 80.05% to $887696.0 in 2023, then soared by 37.03% to $1.2 million in 2024, then surged by 389.32% to $6.0 million in 2025.
  • Per Business Quant, the three most recent readings for CBIO's Non-cash Items are $6.0 million (Q1 2025), $1.2 million (Q3 2024), and $5.6 million (Q2 2024).